ONCONIM BRCA PREVENT2019-01-11T08:30:17+01:00

OncoNIM® BRCA Prevent

Study based on massive sequencing directed to the identification of mutations and to the screening of large rearrangements in the BRCA1/2 genes.

The genetic study of the BRCA1 and BRCA2 genes is indicated in:

  • Identification of patients with hereditary breast and ovarian cancer syndrome
  • In the study of ovarian cancer for the selection of patients candidates for treatment with PARP inhibitors.

Depending on the indication, this study is performed in peripheral blood or in tumor samples.

Reference: ONC2006
Delivery of results: 20 working days from receipt of the sample.

Contact us

Any doubts about OncoNIM® BRCA Prevent?

Send us a message

I accept the privacy policy

Do you prefer that we call you?